Etomidate Improves Antitumor Immunity by Suppressing PD-L1 Expression in Hepatocellular Carcinoma Cells
These findings support the hypothesis that etomidate enhances antitumor immunity and boosts the therapeutic efficacy of immune checkpoint blockade, thereby laying a theoretical foundation for precision immunotherapy in HCC.
Authors
- Yining Chen (ORCID: https://orcid.org/0009-0004-0065-4378)
- Z. Y. Yuan (ORCID: https://orcid.org/0000-0002-6249-7708)
- Lidong Zhang (ORCID: https://orcid.org/0009-0006-1013-918X)
- Jingjing Dai (ORCID: https://orcid.org/0000-0001-8337-7281)
- Yu Xu (ORCID: https://orcid.org/0000-0002-7421-4701)
- Jiali Xu (ORCID: https://orcid.org/0000-0001-7047-7240)
- Qing Li (ORCID: https://orcid.org/0000-0003-3087-4692)
- Zhihui Wang (ORCID: https://orcid.org/0009-0008-0029-8413)
- Cunming Liu (ORCID: https://orcid.org/0000-0003-4935-3758)
- Qing Ji (ORCID: https://orcid.org/0000-0002-6104-4088)
- Dapeng Gao
- Liren Zhang (ORCID: https://orcid.org/0009-0001-7644-9010)
Institutions
- Xuzhou Medical College (CN)
- Nanjing General Hospital of Nanjing Military Command (CN)
- Nanjing Maternity and Child Health Care Hospital (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Cellular and Molecular Gastroenterology and Hepatology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.jcmgh.2025.101652
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 0.00